- Home
- WINT vs CYCC Comparison
WINT vs CYCC Comparison
Compare WINT & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WINT
- CYCC
- Stock Information
- Founded
- WINT 1992
- CYCC 1992
- Country
- WINT United States
- CYCC United States
- Employees
- WINT N/A
- CYCC N/A
- Industry
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- WINT Health Care
- CYCC Health Care
- Exchange
- WINT Nasdaq
- CYCC Nasdaq
- Market Cap
- WINT 2.0M
- CYCC 2.2M
- IPO Year
- WINT 1995
- CYCC N/A
- Fundamental
- Price
- WINT $0.12
- CYCC $0.34
- Analyst Decision
- WINT Hold
- CYCC Strong Buy
- Analyst Count
- WINT 1
- CYCC 1
- Target Price
- WINT $7.00
- CYCC $11.00
- AVG Volume (30 Days)
- WINT 7.3M
- CYCC 6.4M
- Earning Date
- WINT 11-27-2024
- CYCC 03-18-2025
- Dividend Yield
- WINT N/A
- CYCC N/A
- EPS Growth
- WINT N/A
- CYCC N/A
- EPS
- WINT N/A
- CYCC N/A
- Revenue
- WINT N/A
- CYCC $74,000.00
- Revenue This Year
- WINT N/A
- CYCC N/A
- Revenue Next Year
- WINT N/A
- CYCC $88.68
- P/E Ratio
- WINT N/A
- CYCC N/A
- Revenue Growth
- WINT N/A
- CYCC N/A
- 52 Week Low
- WINT $0.11
- CYCC $0.31
- 52 Week High
- WINT $14.75
- CYCC $4.00
- Technical
- Relative Strength Index (RSI)
- WINT 15.60
- CYCC 43.27
- Support Level
- WINT $0.21
- CYCC $0.32
- Resistance Level
- WINT $0.33
- CYCC $0.41
- Average True Range (ATR)
- WINT 0.03
- CYCC 0.03
- MACD
- WINT 0.00
- CYCC -0.00
- Stochastic Oscillator
- WINT 2.15
- CYCC 24.44
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.